NeuroBo Pharmaceuticals Analyst Ratings
NeuroBo Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $6.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $1.42, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1026.76% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 06/15/2020 | 1308.45% | HC Wainwright & Co. | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 12/07/2022 | 322.54% | 拉登堡·塔爾曼 | → 6 美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 1 月 2 日 | 1026.76% | HC 溫賴特 & 有限公司. | 二十元 → 十六美元 | 維護 | 購買 |
| 06/15/2020 | 1308.45% | HC 溫賴特 & 有限公司. | → 20 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for NeuroBo Pharmaceuticals (NRBO)?
神經博藥品（NRBO）的目標價格是多少？
The latest price target for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was reported by Ladenburg Thalmann on December 7, 2022. The analyst firm set a price target for $6.00 expecting NRBO to rise to within 12 months (a possible 322.54% upside). 1 analyst firms have reported ratings in the last year.
拉登堡·塔爾曼於 2022 年 12 月 7 日報導了神經博製藥（納斯達克股票代碼：NRBO）的最新價格目標。該分析師公司設定了 6.00 美元的價格目標，預計 NRBO 將在 12 個月內上升（可能是 322.54％ 的上行情況）。1 家分析師公司在去年報告了評級。
What is the most recent analyst rating for NeuroBo Pharmaceuticals (NRBO)?
神經博製藥（NRBO）的最新分析師評級是什麼？
The latest analyst rating for NeuroBo Pharmaceuticals (NASDAQ: NRBO) was provided by Ladenburg Thalmann, and NeuroBo Pharmaceuticals initiated their buy rating.
NeuroBo 製藥（納斯達克：NRBO）的最新分析師評級由拉登堡·塔爾曼提供，神經博製藥發起了他們的購買評級。
When is the next analyst rating going to be posted or updated for NeuroBo Pharmaceuticals (NRBO)?
NeuroBo 製藥（NRBO）何時將發布或更新下一個分析師評級？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroBo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroBo Pharmaceuticals was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
分析師在做廣泛的研究後到達股票評級，其中包括通過公共財務報表，與 NeuroBo Pharmacery 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。神經博製藥的最後一個評級已於 2022 年 12 月 7 日提交，因此您應該期望下一個評級將在 2023 年 12 月 7 日左右提供。
Is the Analyst Rating NeuroBo Pharmaceuticals (NRBO) correct?
分析師評級 NeuroBO 製藥（NRBO）是否正確？
While ratings are subjective and will change, the latest NeuroBo Pharmaceuticals (NRBO) rating was a initiated with a price target of $0.00 to $6.00. The current price NeuroBo Pharmaceuticals (NRBO) is trading at is $1.42, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的 Neurobo 藥品（NRBO）評級是啟動的，目標價格為 0.00 美元至 6.00 美元。目前的價格神經博製藥（NRBO）的交易價格為 1.42 美元，這是分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
